Novo Nordisk's parent to buy Catalent for $16.5 bln to boost Wegovy supply
Novo Nordisk's parent to buy Catalent for $16.5 bln to boost Wegovy supply
Upworthy
0 shares
1 views
You might like
Related news coverage
Astrazeneca says Catalent deal shows need for in-house capacity
Upworthy
The sale of listed contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance for big pharma..
-
With Novo Nordisk's Wegovy weight-loss drug in short supply, the company's owner agreed to buy contract manufacturer Catalent for $16.5 billion, including…
Upworthy
-
Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production
Upworthy
-
Novo Nordisk parent buys US drug firm for $16.5bn to expand Wegovy supply
Upworthy
-
Wegovy maker Novo inks $16.5 billion acquisition of Catalent to boost supply
Upworthy
Advertisement
More coverage
Stock Pops 10% on Sale to Novo Nordisk
Upworthy
CTLT stock is up with heavy trading on the news Catalent (NYSE:CTLT) stock is climbing higher on Monday after the company agreed to..